Pharmaceutical Company Jelfa SA – FDA Warning Letter

On July 14, 2011, the FDA issued a Warning Letter to Pharmaceutical Company Jelfa SA following an October 2010 inspection of their Jelenia Gora, Poland facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations included: 1. **Inadequate Investigation of Batch Failures:** Jelfa SA failed to thoroughly investigate a sterility test failure for (b)(4) Injection, batch # (b)(4). A retest was performed without conclusive assignable laboratory cause, which is unacceptable. Despite the lot's eventual rejection, no investigation into the manufacturing process or facility controls was conducted to identify the root cause, raising concerns about other potentially affected batches. The FDA requested the final sterility failure investigation report, root cause analysis, corrective actions, and details on media fills. 2. **Failure to Prevent Microbiological Contamination:** The firm lacked appropriate written procedures to prevent microbiological contamination of sterile drug products. Specific observations included poor aseptic techniques during filling (e.g., exposed facial skin, improper use of forceps), employees performing critical duties not participating in media fills, unprotected tubing ends prior to sterilization, and incomplete disinfectant efficacy studies. 3. **Inadequate Quality Control Unit Responsibilities:** The quality control unit failed to adequately exercise its responsibilities, particularly